Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
vibostolimab (MK-7684)
i
Other names:
MK-7684, MK 7684, MK7684
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
Merck (MSD)
Drug class:
TIGIT inhibitor
Related drugs:
‹
AB154 (5)
BGB-A1217 (5)
RG6058 (3)
HB0030 (1)
EOS-448 (1)
AZD2936 (1)
IBI-939 (1)
ASP8374 (0)
AUR-106 (0)
BAT6005 (0)
COM902 (0)
DSP502 (0)
HB0036 (0)
HLX-53 (0)
JS006 (0)
MG1131 (0)
PH-804 TME (0)
PM1022 (0)
SEA-TGT (0)
SL-9258 (0)
Undisclosed TIGIT ETB (0)
ZG005 (0)
ZGGS15 (0)
M6223 (0)
MPH-313 (0)
AK127 (0)
AB308 (0)
BMS-986207 (0)
MK-7684A (0)
AB154 (5)
BGB-A1217 (5)
RG6058 (3)
HB0030 (1)
EOS-448 (1)
AZD2936 (1)
IBI-939 (1)
ASP8374 (0)
AUR-106 (0)
BAT6005 (0)
COM902 (0)
DSP502 (0)
HB0036 (0)
HLX-53 (0)
JS006 (0)
MG1131 (0)
PH-804 TME (0)
PM1022 (0)
SEA-TGT (0)
SL-9258 (0)
Undisclosed TIGIT ETB (0)
ZG005 (0)
ZGGS15 (0)
M6223 (0)
MPH-313 (0)
AK127 (0)
AB308 (0)
BMS-986207 (0)
MK-7684A (0)
›
Associations
(1)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003) (KeyVibe-003) (NCT04738487)
Phase 3
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Recruiting
Phase 3
Merck Sharp & Dohme LLC
Recruiting
Last update posted :
06/14/2024
Initiation :
04/07/2021
Primary completion :
04/21/2026
Completion :
06/05/2028
EGFR • PD-L1 • ALK • ROS1 • PD-1
|
PD-L1 expression
|
Keytruda (pembrolizumab) • vibostolimab (MK-7684) • vibostolimab/pembrolizumab (MK-7684A)
Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001) (NCT02964013)
Phase 1
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Active, not recruiting
Phase 1
Merck Sharp & Dohme LLC
Active, not recruiting
Last update posted :
04/18/2024
Initiation :
12/13/2016
Primary completion :
08/01/2024
Completion :
08/01/2024
HER-2
|
Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • etoposide IV • vibostolimab (MK-7684) • vibostolimab/pembrolizumab (MK-7684A)
Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002) (NCT04725188)
Phase 2
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Active, not recruiting
Phase 2
Merck Sharp & Dohme LLC
Active, not recruiting
Last update posted :
04/02/2024
Initiation :
04/20/2021
Primary completion :
01/26/2023
Completion :
08/13/2027
EGFR • ALK
|
Keytruda (pembrolizumab) • docetaxel • vibostolimab (MK-7684) • vibostolimab/pembrolizumab (MK-7684A)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login